HimalayasHimalayas logo
Summit TherapeuticsST

Director, Biostatistics

Summit Therapeutics is a biopharmaceutical oncology company focused on discovering, developing, and commercializing novel therapies to treat cancer, with its lead candidate ivonescimab undergoing multiple Phase 3 clinical trials.

Summit Therapeutics

Employee count: 201-500

Salary: 203k-253k USD

United States only

Stay safe on Himalayas

Never send money to companies. Jobs on Himalayas will never require payment from applicants.

About Summit:

Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit’s core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence.

Summit’s team is inspired to touch and help change lives through Summit’s clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including:

Non-small Cell Lung Cancer (NSCLC)

  • HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI.

  • HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC.

  • HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC.

Colorectal Cancer (CRC)

  • HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy.

Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA). Summit is headquartered in Miami, Florida, and has additional offices in California, New Jersey, the UK, and Ireland.

Overview of Role:

Serves as the project level biostatistician and provides leadership within biostatistics function to develop and execute statistical strategy, study design, statistical analyses, and regulatory submissions for clinical trials in oncology. Partners with clinical science, regulatory and other team members in clinical development plans, authoring key clinical/regulatory/statistical documents, and ensuring exceptional delivery and interpretation of clinical data. Develops and implements biostatistics department policies, standards, procedures, and work-instructions in coordination with department leader and other functions. Represents biostatistics function in interactions with CROs, institutional review boards, and regulatory agencies.

Role and Responsibilities:

  • Provide technical leadership and statistical support to clinical development through the design and conduct of clinical studies in oncology
  • Support/contribute to protocol development to ensure appropriateness of trial design, sample size, and propose the use of meaningful and efficient statistical methodologies
  • Lead development of statistical analysis plans, data presentation plans, clinical development plans, biometrics related submission activities, and post-submission strategies/responses
  • Review the accuracy of clinical data, perform statistical analysis, interpret study results, and collaborate with clinical team and other team members to produce interim reports, final reports, and publications
  • Write/review sections of meeting packages and assist in the development and review of other documents required for regulatory submissions and other regulatory processes
  • Review vendor data transfer specifications and ADaM programming specifications
  • Lead assessment and introduction of novel statistical methodologies to implement solutions
  • Represent biostatistics function or biometrics department in cross function teams
  • Work with department leader to develop and implement department policies, standards and procedures
  • Collaborate with clinical operations, data management and CRO to develop and implement CRFs, database design, and the overall data quality plan
  • Evaluate and manage CROs and other vendors, including scope-of-work, timelines, deliverables and budgets
  • Provide strategic statistical and regulatory guidance to anticipate challenges, mitigate risk, and ensure project success
  • Attend meetings with FDA or other health authorities to ensure ongoing agreement on project development
  • All other duties as assigned

Experience, Education and Specialized Knowledge and Skills:

  • PhD and a minimum of 8+ years of experience or Masters (MS) and a minimum of 11+ years of experience in statistics or biostatistics or related disciplines with clinical trials, pharmaceutical/biotech industry, or healthcare experience
  • Experience in supporting oncology phase II/III clinical studies
  • Experience in organizing and driving regulatory submissions (e.g. NDA, sNDA, BLA)
  • In-depth knowledge of CDISC standards
  • Technical expertise and knowledge of experimental design and analyses using SAS, R, or EAST, and etc.
  • Excellent written and verbal communication skills
  • Good working knowledge of ICH, FDA and GCP regulations and guidelines

This is the pay for this position

Pay Transparency
$203,000—$253,000 USD

Actual compensation packages are based on several factors that are unique to each candidate, including but not limited to skill set, depth of experience, certifications, and specific work location. This may be different in other locations due to differences in the cost of labor. The total compensation package for this position may also include bonus, stock, benefits and/or other applicable variable compensation.

Summit does not accept referrals from employment businesses and/or employment agencies in respect of the vacancies posted on this site. All employment businesses/agencies are required to contact Summit’s Talent Acquisition team at recruiting@smmttx.com to obtain prior written authorization before referring any candidates to Summit.

Summit Therapeutics Inc. is an Equal Opportunity Employer and takes pride in creating and maintaining diverse environment. We do not discriminate in recruitment, hiring, training or promotion or any other employment practices for reasons of race, color, religion, gender, national origin, age, sexual orientation, marital or veteran status, disability, or any other legally protected status.

About the job

Apply before

Posted on

Job type

Full Time

Experience level

Salary

Salary: 203k-253k USD

Education

Postgraduate degree

Experience

8 years minimum

Location requirements

Hiring timezones

United States +/- 0 hours

About Summit Therapeutics

Learn more about Summit Therapeutics and their company culture.

View company profile

Summit Therapeutics Inc. is a biopharmaceutical oncology company committed to the discovery, development, and commercialization of patient-, physician-, caregiver-, and societal-friendly medicinal therapies. The company's mission focuses on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs, particularly in the field of oncology.

Headquartered in Miami, Florida, with additional offices in Palo Alto, California; Princeton, New Jersey; Oxford, UK; and Dublin, Ireland, Summit Therapeutics has positioned itself as a leader in cancer treatment innovation. The company's lead pipeline candidate is ivonescimab, a novel bispecific antibody targeting both PD-1 and VEGF. In January 2023, Summit established a collaboration and license agreement with Akeso, Inc. for ivonescimab, gaining rights to develop and commercialize the therapy in the United States, Canada, Europe, Japan, Latin America, the Middle East, and Africa.

Summit is currently conducting multiple global Phase 3 clinical trials for ivonescimab, including studies in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). The company has initiated several Phase 3 trials including HARMONi, HARMONi-3, HARMONi-7, and HARMONi-GI3, demonstrating a commitment to advancing oncology treatment options. With a leadership team that has a proven track record in drug development, regulatory approval, and commercialization, Summit is positioning itself for durable growth while maintaining its focus on patient-centered innovation.

Employee benefits

Learn about the employee benefits and perks provided at Summit Therapeutics.

View benefits

401(k) Match

6% 401k match offered to employees

On-site Lunch

Lunch provided on-site for employees

Paid Time Off

15 vacation days and 6 sick days provided annually

Stock Options

Stock options granted to employees, vested once a year

View Summit Therapeutics's employee benefits
Claim this profileSummit Therapeutics logoST

Summit Therapeutics

View company profile

Similar remote jobs

Here are other jobs you might want to apply for.

View all remote jobs

8 remote jobs at Summit Therapeutics

Explore the variety of open remote roles at Summit Therapeutics, offering flexible work options across multiple disciplines and skill levels.

View all jobs at Summit Therapeutics

Remote companies like Summit Therapeutics

Find your next opportunity by exploring profiles of companies that are similar to Summit Therapeutics. Compare culture, benefits, and job openings on Himalayas.

View all companies

Find your dream job

Sign up now and join over 100,000 remote workers who receive personalized job alerts, curated job matches, and more for free!

Sign up
Himalayas profile for an example user named Frankie Sullivan